Morphologic reproducibility, genotyping, and immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary

American Journal of Surgical Pathology

Volumn 41, Issue 5, 2017, Pages 685-695

  Rambau, Peter F ^a,c   McIntyre, John B ^b   Taylor, Jennifer ^d   Lee, Sandra ^a   Ogilvie, Travis ^a   Sienko, Anna ^a   Morris, Don ^a,b   Duggan, Máire A ^a   McCluggage, W Glenn ^d   Köbel, Martin ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Endocervical Type mucinous; Endometrioid; Low grade serous; Mixed cell type; Mixed m llerian; Seromucinous

Indexed keywords

TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BIOPSY; CANCER GRADING; CANCER STAGING; CARCINOMA, ENDOMETRIOID; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR DIAGNOSIS; MUTATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NOMENCLATURE; OBSERVER VARIATION; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; REPRODUCIBILITY; TISSUE MICROARRAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, ENDOMETRIOID; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OBSERVER VARIATION; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TERMINOLOGY AS TOPIC; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 85010876736     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000812     Document Type: Article

References (39)

1. Kö bel M, Bell DA, Carcangiu MA, et al. WHO classification of tumours of female reproductive organs: seromucinous tumors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. World Health Organization. Lyon: International Agency for Research on Cancer; 2014:38-40.
2. Lee KR, Tavassoli FA, Prat J, et al. WHO classification of tumors of the breast and female genital organs: surface epithelia-stromal tumors. In: Tavassoli FA, Devilee P, eds. World Health Organization. Lyon: International Agency for Research on Cancer; 2003:117-161.
3. Rutgers JKL. Mullerian mucinous/mixed epithelial (seromucinous) ovarian tumors. Am J Surg Pathol Reviews & Reports. 2016;21:206-213.
4. Taylor J, McCluggage WG. Ovarian seromucinous carcinoma: Report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol. 2015;39:983-992.
5. Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-Type mucinous and mixed cell-Type) tumors: Atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529-1541.
6. Kurman RJ, Shih Ie M. Seromucinous tumors of the ovary. What's in a name? Int J Gynecol Pathol. 2016;35:78-81.
7. Rutgers JL, Scully RE. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer. 1988;61:340-348.
8. Wu CH, Mao TL, Vang R, et al. Endocervical-Type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol. 2012;31:297-303.
9. Kim KR, Choi J, Hwang JE, et al. Endocervical-like (Mullerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. Histopathology. 2010;57:587-596.
10. Kö bel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014;64:1004-1013.
11. Kö bel M, Rahimi K, Rambau PF, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35:430-441.
12. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol. 2006;25:83-89.
13. Yasunaga M, Ohishi Y, Oda Y, et al. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol. 2009;40:965-974.
14. Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. Am J Pathol. 2016;186: 733-747.
15. Chen W, Husain A, Nelson GS, et al. Immunohistochemical profiling of endometrial serous carcinoma. Int J Gynecol Pathol. 2016. [Epub ahead of print].
16. Rambau PF, Duggan MA, Ghatage P, et al. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. Histopathology. 2016;69:288-297.
17. Kö bel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2:247-258.
18. Grisham RN, Sylvester BE, Won H, et al. Extreme outlier analysis identifies occult mitogen-Activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer. J Clin Oncol. 2015;33:4099-4105.
19. McIntyre J, Rambau PF, Chan A, et al. Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma. Histopathology. 2016. Doi:10.1111/his.13071. [Epub ahead of print].
20. McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014;27:128-134.
21. Kandoth C, McLellan MD, Vandin F, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
22. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas. N Engl J Med. 2010;363:1532-1543.
23. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597-1601.
24. Mackenzie R, Kommoss S, Winterhoff BJ, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015;15:415.
25. Stewart CJ, Walsh MD, Budgeon CA, et al. Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: correlation with KRAS mutation and the presence of endometriosis. Pathology. 2013;45:559-566.
26. Stewart CJ, Leung Y, Walsh MD, et al. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: Association with concurrent endometriosis. Hum Pathol. 2012;43:1177-1183.
27. Xiong J, He M, Jackson C, et al. Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of k-ras mutations: A morphologic and molecular correlation study. Int J Gynecol Cancer. 2013;23:1231-1236.
28. Nodin B, Zendehrokh N, Sundström M, et al. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol. 2013;25:106.
29. Nout RA, Bosse T, Creutzberg CL, et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/bcatenin and P53 pathway activation. Gynecol Oncol. 2012;126:466-473.
30. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-Talk and compensation. Trends Biochem Sci. 2011;36:320-328.
31. Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2, 433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.
32. Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pangenomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;30:363.
33. Kim A, Lee JE, Lee SS, et al. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer. 2013;133:984-996.
34. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351-1356.
35. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1:170-185.
36. Silva EG, Young RH. Endometrioid neoplasms with clear cells: A report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol. 2007;31:1203-1208.
37. Conklin CMJ, Gilks CB. Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. Expert Rev Obstet Gynecol. 2013;8:67-82.
38. Silva EG, Deavers MT, Malpica A. Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae. Int J Gynecol Pathol. 2010;29:507-512.
39. Stewart CJ, Brennan BA, Chan T, et al. WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology. 2008;40:592-599.